FBIO

Fortress Biotech, Inc.

1.91

USD

-0.08

-4.02%

Nov 10, 15:59 UTC -5

Closed

After-Market

2.00

+0.09

+4.71%

Fortress Biotech, Inc. (FBIO) Earnings

FBIO Earnings Reports

Positive Surprise Ratio

FBIO beat 24 of 42 last estimates.

57%

Next Report

In 2 Days

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

$22.01M

-$0.27

Implied change from Q2 26 (Revenue/ EPS)

+17.57%

+237.50%

Implied change from Q3 25 (Revenue/ EPS)

+24.82%

-345.45%

Fortress Biotech, Inc. earnings per share and revenue

On Aug 13, 2026, FBIO reported earnings of -0.08 USD per share (EPS) for Q2 26, beating the estimate of -0.20 USD, resulting in a 60.78% surprise. Revenue reached 18.72 million, compared to an expected 18.67 million, with a 0.28% difference. The market reacted with a -1.68% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.27 USD, with revenue projected to reach 22.01 million USD, implying an increase of 237.50% EPS, and increase of 17.57% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Fortress Biotech, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Fortress Biotech, Inc. reported EPS of -$0.08, beating estimates by 60.78%, and revenue of $18.72M, 0.28% above expectations.

How did the market react to Fortress Biotech, Inc.'s Q2 2026 earnings?

The stock price moved down -1.68%, changed from $2.98 before the earnings release to $2.93 the day after.

When is Fortress Biotech, Inc. expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for Fortress Biotech, Inc.'s next earnings report?

Based on -- analysts, Fortress Biotech, Inc. is expected to report EPS of -$0.27 and revenue of $22.01M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.